Anthropic launches ‘Claude Science’: Here’s what researchers need to know

Anthropic has reportedly launched an AI research application, Claude Science, designed to help scientists optimize research, analyze data, and streamline complex computing workflows.

This launch is part of Anthropic’s life sciences and healthcare initiative, which the company has been progressing since October 2025.

Claude Science is primarily an application that incorporates the tools and packages that researchers most commonly use, and provides on-demand access to computing resources.

The tool is pre-programmed with more than 60 scientific databases and can render scientific artifacts such as 3D protein structures, genome browser tracks and chemistry drawings.

How it works

Claude Science documents figures and manuscripts alongside the code that created them. It displays complex academic deliverables, including 3D protein structures, genome browser tracks, and more.

One can chat with the agent about any detail, interpreting images and manuscripts inline so the agent knows what to address to make them publication ready.

Anthropic is also introducing its own non-clinical development programs focused on neglected diseases, as revealed by the AI startup’s head of life sciences, Eric Kauderer-Abrams during a press briefing.

“These are areas that are outside the scope of what the ⁠traditional pharma ​and biotech landscape might consider ​attractive targets, but nonetheless have real burden associated with them,” Kauderer-Abrams said.

The Claude Science app is available in beta on macOS and Linux for the Pro, Max, Team, and Enterprise plans. The company clarified that this information is specifically shared for projects that extend domains and expand the frontiers of science with an early focus on biology and biomedical research.

Anthropic is all set to see its first profitable quarter, and if major commitments with pharmaceutical companies come through that would ultimately help ensure it stays profitable as the “tokenmaxxing” craze tapers off-something that’s more crucial than ever as an IPO approaches this year.